Omidenepag isopropyl (DE-117) is a selective prostaglandin EP2 receptor agonist and a novel topical ocular blood pressure lowering compound.Omidenepag isopropyl has a weak affinity for EP1, EP2, and FP receptors.Omidenepag isopropyl is used in studies of glaucoma and hypertension. Omidenepag isopropyl can be used to study glaucoma and hypertension.

METHODS: All binding studies were performed on prostaglandin receptors DP1, EP1-4, FP, and IP at OMDI (0.1, 0.3, 1, 3, and 10 μM) in all assays, calculated using the Cheng-Prusoff equation.
RESULTS: OMDI binds weakly to the EP1 receptor with Ki = 1700 nM, to the EP2 receptor with Ki > 4600 nM, and to the FP receptor with Ki > 4500 nM. [2]

METHODS: The effects of Omidenepag isopropyl on intraocular pressure and aqueous humor dynamics were evaluated in cynomolgus monkeys with unilateral laser-induced intraocular hypertension. In a crossover fashion, the hypertensive eye of each monkey was dosed once daily with 20 μL of 0.002% Omidenepag isopropyl or vehicle. On day 7 of dosing, IOP was measured by pneumometry, aqueous humor flow and outflow facilities were assessed by fluorophotometry, and uveoscleral outflow was calculated mathematically. Treatments were compared by paired t test.
RESULTS: Omidenepag isopropyl significantly reduced intraocular pressure by 27%, 35% and 44% at 0.5, 1.5 and 4 hours after the last administration; Omidenepag isopropyl treatment group and uveoscleral outflow significantly increased by 71% and 176% respectively. (P<0.05). [1]

DMSO: 40 mg/mL (76.83 mM), Sonication is recommended.